Agency Information Collection Activities: Submission for OMB Review; Comment Request, 61108-61110 [2011-25374]
Download as PDF
<![CDATA[
61108
Federal Register / Vol. 76, No. 191 / Monday, October 3, 2011 / Notices
anonymity. Counselors will be asked to
complete the form for 100% of
imminent risk callers to the eight
centers participating in the evaluation.
This form requests information in 14
content areas, each with multiple subitems and response options. Response
options include open-ended, yes/no,
Likert-type ratings, and multiple choice/
check all that apply. The form also
requests demographic information on
the caller, the identification of the
center and counselor submitting the
form, and the date of the call.
Specifically, the form is divided into the
following sections: (1) Call type, (2)
gender, (3) age, (4) suicidal desire, (5)
suicidal intent, (6) suicidal capability,
(7) buffers to suicide, (8) interventions
agreed to by caller or implemented by
counselor without consent, (9) whether
imminent risk was reduced enough such
that active rescue was not needed, (10)
interventions for third party callers
calling about a person at imminent risk,
(11) if supervisory consultation
occurred, (12) barriers to getting needed
help to the person at imminent risk, (13)
steps taken to confirm emergency
contact was made with person at risk,
and (14) steps taken when emergency
contact was NOT made with person at
risk. The form will take approximately
15 minutes to complete and may be
completed by the counselor during or
after the call. It is expected that a total
of 1,440 forms will be completed by 360
counselors over the two-year data
collection period.
The estimated response burden to
collect this information is annualized
over the requested two-year clearance
period and is presented below:
TOTAL AND ANNUALIZED AVERAGES: RESPONDENTS, RESPONSES AND HOURS
Instrument
Number of
respondents
Responses/
respondent
Total
responses
Hours per
response
Total hour
burden
National Suicide Prevention Lifeline—Imminent Risk Form
360
2
720
.25
180
Written comments and
recommendations concerning the
proposed information collection should
be sent by November 2, 2011 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via e-mail to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via e-mail,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Rose Shannon,
Director, Division of Executive
Correspondence.
[FR Doc. 2011–25375 Filed 9–30–11; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
srobinson on DSK4SPTVN1PROD with NOTICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
VerDate Mar<15>2010
16:42 Sep 30, 2011
Jkt 223001
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Cross-Site Evaluation of the
Minority Substance Abuse/HIV
Prevention Program—(OMB No. 0930–
0298)—Revision
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting from
the Office of Management and Budget
(OMB) approval for the revision of data
collection activities for the cross-site
study of the Minority HIV/AIDS
Initiative (MAI), which includes both
youth and adult questionnaires. This
revision includes the addition of 4
cohorts, changes to the data collection
procedures based on intervention
duration, and the addition of two
questions on binge drinking behavior.
The current approval is under OMB No.
0930–0298, which expires on 4/30/12.
This cross-site evaluation supports
two of SAMHSA’s 8 Strategic Initiatives:
Prevention of Substance Abuse and
Mental Illness and Data, Outcomes, and
Quality. It builds on six previous grant
programs funded by SAMHSA’s CSAP
to provide substance abuse and HIV
prevention services for minority
populations. The first two were
planning grant programs and the last
four were service grant programs. The
goals for the Cohort 3–6 grants were to
add, increase, or enhance integrated
substance abuse (SA) and HIV
prevention services by providing
supportive services and strengthening
linkages between service providers for
at-risk minority populations. The HIV
Cohort 1–3 previously received
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
clearance under OMB No. 0930–0208
and Cohort 6 grants previously received
clearance under OMB No. 0930–0298.
Since neither the HIV Cohort 4 nor the
Cohort 5 Programs were cross-site
studies, they did not require OMB
clearance. The current HIV Minority
SA/HIV Prevention Program funded:
• Cohorts 7 and 8 Prevention of
Substance Abuse (SA) and HIV for AtRisk Racial/Ethnic Minority
Subpopulations Cooperative
Agreements—60 grants for 5 years,
• Cohort 9 Ready-To-Respond
Initiative—35 grants for 5 years and,
• Cohort 10 Capacity Building
Initiative—27 grants for 5 years.
Grantees are community based
organizations that are required to
address the SAMHSA Strategic
Prevention Framework (SPF) and
participate in this cross-site evaluation.
The grantees are expected to provide
leadership and coordination on the
planning and implementation of the
SPF that targets minority populations,
the minority reentry population, as well
as other high risk groups residing in
communities of color with high
prevalence of SA and HIV/AIDS. The
primary objectives of the cross-site
study are to: (1) Determine the success
of the MAI in preventing, delaying, and/
or reducing the use of alcohol, tobacco,
and other drugs (ATOD) among the
target populations. The results of this
cross-site study will assist SAMHSA/
CSAP in promoting and disseminating
optimally effective prevention
programs; (2) Measure the effectiveness
of evidence-based programs and
infrastructure development activities
such as: outreach and training,
mobilization of key stakeholders,
substance abuse and HIV/AIDS
E:\FR\FM\03OCN1.SGM
03OCN1
61109
Federal Register / Vol. 76, No. 191 / Monday, October 3, 2011 / Notices
counseling and education, referrals to
appropriate medical treatment and/or
other intervention strategies (i.e.,
cultural enrichment activities,
educational and vocational resources,
and computer-based curricula); and (3)
Assess the process of adopting and
implementing the Strategic Prevention
Framework (SPF) with the target
populations.
The grantees are expected to provide
an effective prevention process,
direction, and a common set of goals,
expectations, and accountabilities to be
adapted and integrated at the
community level. While the grantees
have substantial flexibility in choosing
their individual evidence-based
programs, they are all required to base
them on the five steps of the SPF to
build service capacity specific to SA
and HIV prevention services.
Conducting this cross-site evaluation
will assist SAMHSA/CSAP in
promoting and disseminating optimally
effective prevention programs.
Grantees must also conduct ongoing
monitoring and evaluation of their
projects to assess program effectiveness
including Federal reporting of the
Government Performance and Results
Act (GPRA) of 1993, SAMHSA/CSAP
National Outcome Measures (NOMs),
and HIV Counseling and Testing. All of
this information will be collected
through self-report questionnaires
administered to program participants.
All grantees will use two instruments,
one for youth aged between 12 and 17
and one for adults aged 18 and older.
Participants in interventions lasting 30
days or longer will complete
questionnaires three times, taking an
average of 50 minutes for baseline, exit,
and follow-up questionnaires.
Participants in interventions lasting 2–
29 days will complete questionnaires
two times taking an average of 30
minutes to complete. Single-session
intervention participants will complete
one questionnaire at exit only. The
GPRA and NOMs measures on the
instruments have already been approved
by OMB (OMB No. 0930–0230), and the
remaining HIV-related questions have
been approved under OMB No. 0930–
0298.The youth questionnaire contains
125 questions, of which 28 relate to
HIV/AIDS and the adult questionnaire
contains 118 items, 47 of which relate
to HIV/AIDS. Two additional questions
have been added to address SAMHSA’s
need to collect information on binge
drinking behavior.
These questions are:
1. Females only: During the past 30
days, on how many days did you have
4 or more drinks on the same occasion?
2. Males only: During the past 30
days, on how many days did you have
5 or more drinks on the same occasion?
Sample size, respondent burden, and
intrusiveness have been minimized to
be consistent with the cross-site
objectives. Procedures are employed to
safeguard the privacy and
confidentiality of participants. Every
effort has been made to coordinate
cross-site data collection with local data
collection efforts in an attempt to
minimize respondent burden.
The cross-site evaluation results will
have significant implications for the
substance abuse and HIV/AIDS
prevention fields, the allocation of grant
funds, and other evaluation activities
conducted by multiple Federal, State,
and local government agencies. They
will be used to develop Federal policy
in support of SAMHSA/CSAP program
initiatives, inform the public of lessons
learned and findings, improve existing
programs, and promote replication and
dissemination of effective prevention
strategies.
Total Estimates of Annualized Hour
Burden
The following table shows the
estimated annualized burden for data
collection.
TABLE 1A—ESTIMATES OF ANNUALIZED HOUR BURDEN BY INTERVENTION LENGTH
Number of
respondents
Intervention length
30-Days or More Intervention:
Base line .......................................................................
Exit ................................................................................
Follow-up ......................................................................
Subtotal .........................................................................
2 to 29 Day Intervention:
Base line .......................................................................
Exit ................................................................................
Subtotal .........................................................................
Single Day Intervention:
Exit ................................................................................
Annualized Total ...........................................................
Responses
per
respondent
Total
responses
Hours per
response
Total hour
burden
7,937
4,887
2,942
7,937
1
1
1
........................
7,937
4,887
2,942
15,766
0.83
0.83
0.83
........................
6,588
4,056
2442
13,086
1,416
872
1,416
1
1
........................
1,416
872
2,288
0.5
0.5
........................
708
436
1,144
2,458
11,811
1
........................
2,458
20,512
0.25
........................
614
14,844
TABLE 1B—ESTIMATES OF ANNUALIZED HOUR BURDEN BY SURVEY TYPE
Questionnaire
Number of respondents
Total responses
Total hour burden
9,682
2,128
16,899
3,612
12,234
2,610
Annualized Total ..............................
srobinson on DSK4SPTVN1PROD with NOTICES
Annualized Total Adult ...................................
Annualized Total Youth .................................
11,811
20,512
14,844
Written comments and
recommendations concerning the
proposed information collection should
be sent by November 2, 2011 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
VerDate Mar<15>2010
16:42 Sep 30, 2011
Jkt 223001
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
their comments to OMB via e-mail to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via e-mail,
commenters may also fax their
comments to: 202–395–7285.
E:\FR\FM\03OCN1.SGM
03OCN1
61110
Federal Register / Vol. 76, No. 191 / Monday, October 3, 2011 / Notices
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Rose Shannon,
Director, Division of Executive
Correspondence.
[FR Doc. 2011–25374 Filed 9–30–11; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:42 Sep 30, 2011
Jkt 223001
2–1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires {or set}
strict standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016. (Formerly:
Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150.
Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400. (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433 –3823. (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130. (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783.
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center.)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281.
DrugScan, Inc., P.O. Box 2969, 1119
Mearns Road, Warminster, PA 18974,
215–674–9310.
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Gamma-Dynacare Medical
Laboratories,* A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630.
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986.
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984.
(Formerly: LabCorp Occupational
Testing Service Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group.)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339. (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845.
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Maxxam Analytics,* 6740 Campobello
Road, Mississauga, ON, Canada L5N
2L8, 905–817–5700. (Formerly:
Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
E:\FR\FM\03OCN1.SGM
03OCN1
]]>Agencies
[Federal Register Volume 76, Number 191 (Monday, October 3, 2011)]
[Notices]
[Pages 61108-61110]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-25374]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.
Project: Cross-Site Evaluation of the Minority Substance Abuse/HIV
Prevention Program--(OMB No. 0930-0298)--Revision
The Substance Abuse and Mental Health Services Administration
(SAMHSA), Center for Substance Abuse Prevention (CSAP) is requesting
from the Office of Management and Budget (OMB) approval for the
revision of data collection activities for the cross-site study of the
Minority HIV/AIDS Initiative (MAI), which includes both youth and adult
questionnaires. This revision includes the addition of 4 cohorts,
changes to the data collection procedures based on intervention
duration, and the addition of two questions on binge drinking behavior.
The current approval is under OMB No. 0930-0298, which expires on 4/30/
12.
This cross-site evaluation supports two of SAMHSA's 8 Strategic
Initiatives: Prevention of Substance Abuse and Mental Illness and Data,
Outcomes, and Quality. It builds on six previous grant programs funded
by SAMHSA's CSAP to provide substance abuse and HIV prevention services
for minority populations. The first two were planning grant programs
and the last four were service grant programs. The goals for the Cohort
3-6 grants were to add, increase, or enhance integrated substance abuse
(SA) and HIV prevention services by providing supportive services and
strengthening linkages between service providers for at-risk minority
populations. The HIV Cohort 1-3 previously received clearance under OMB
No. 0930-0208 and Cohort 6 grants previously received clearance under
OMB No. 0930-0298. Since neither the HIV Cohort 4 nor the Cohort 5
Programs were cross-site studies, they did not require OMB clearance.
The current HIV Minority SA/HIV Prevention Program funded:
Cohorts 7 and 8 Prevention of Substance Abuse (SA) and HIV
for At-Risk Racial/Ethnic Minority Subpopulations Cooperative
Agreements--60 grants for 5 years,
Cohort 9 Ready-To-Respond Initiative--35 grants for 5
years and,
Cohort 10 Capacity Building Initiative--27 grants for 5
years.
Grantees are community based organizations that are required to
address the SAMHSA Strategic Prevention Framework (SPF) and participate
in this cross-site evaluation. The grantees are expected to provide
leadership and coordination on the planning and implementation of the
SPF that targets minority populations, the minority reentry population,
as well as other high risk groups residing in communities of color with
high prevalence of SA and HIV/AIDS. The primary objectives of the
cross-site study are to: (1) Determine the success of the MAI in
preventing, delaying, and/or reducing the use of alcohol, tobacco, and
other drugs (ATOD) among the target populations. The results of this
cross-site study will assist SAMHSA/CSAP in promoting and disseminating
optimally effective prevention programs; (2) Measure the effectiveness
of evidence-based programs and infrastructure development activities
such as: outreach and training, mobilization of key stakeholders,
substance abuse and HIV/AIDS
[[Page 61109]]
counseling and education, referrals to appropriate medical treatment
and/or other intervention strategies (i.e., cultural enrichment
activities, educational and vocational resources, and computer-based
curricula); and (3) Assess the process of adopting and implementing the
Strategic Prevention Framework (SPF) with the target populations.
The grantees are expected to provide an effective prevention
process, direction, and a common set of goals, expectations, and
accountabilities to be adapted and integrated at the community level.
While the grantees have substantial flexibility in choosing their
individual evidence-based programs, they are all required to base them
on the five steps of the SPF to build service capacity specific to SA
and HIV prevention services. Conducting this cross-site evaluation will
assist SAMHSA/CSAP in promoting and disseminating optimally effective
prevention programs.
Grantees must also conduct ongoing monitoring and evaluation of
their projects to assess program effectiveness including Federal
reporting of the Government Performance and Results Act (GPRA) of 1993,
SAMHSA/CSAP National Outcome Measures (NOMs), and HIV Counseling and
Testing. All of this information will be collected through self-report
questionnaires administered to program participants. All grantees will
use two instruments, one for youth aged between 12 and 17 and one for
adults aged 18 and older. Participants in interventions lasting 30 days
or longer will complete questionnaires three times, taking an average
of 50 minutes for baseline, exit, and follow-up questionnaires.
Participants in interventions lasting 2-29 days will complete
questionnaires two times taking an average of 30 minutes to complete.
Single-session intervention participants will complete one
questionnaire at exit only. The GPRA and NOMs measures on the
instruments have already been approved by OMB (OMB No. 0930-0230), and
the remaining HIV-related questions have been approved under OMB No.
0930-0298.The youth questionnaire contains 125 questions, of which 28
relate to HIV/AIDS and the adult questionnaire contains 118 items, 47
of which relate to HIV/AIDS. Two additional questions have been added
to address SAMHSA's need to collect information on binge drinking
behavior.
These questions are:
1. Females only: During the past 30 days, on how many days did you
have 4 or more drinks on the same occasion?
2. Males only: During the past 30 days, on how many days did you
have 5 or more drinks on the same occasion?
Sample size, respondent burden, and intrusiveness have been
minimized to be consistent with the cross-site objectives. Procedures
are employed to safeguard the privacy and confidentiality of
participants. Every effort has been made to coordinate cross-site data
collection with local data collection efforts in an attempt to minimize
respondent burden.
The cross-site evaluation results will have significant
implications for the substance abuse and HIV/AIDS prevention fields,
the allocation of grant funds, and other evaluation activities
conducted by multiple Federal, State, and local government agencies.
They will be used to develop Federal policy in support of SAMHSA/CSAP
program initiatives, inform the public of lessons learned and findings,
improve existing programs, and promote replication and dissemination of
effective prevention strategies.
Total Estimates of Annualized Hour Burden
The following table shows the estimated annualized burden for data
collection.
Table 1a--Estimates of Annualized Hour Burden by Intervention Length
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total Hours per Total hour
Intervention length respondents respondent responses response burden
----------------------------------------------------------------------------------------------------------------
30-Days or More Intervention:
Base line................... 7,937 1 7,937 0.83 6,588
Exit........................ 4,887 1 4,887 0.83 4,056
Follow-up................... 2,942 1 2,942 0.83 2442
Subtotal.................... 7,937 .............. 15,766 .............. 13,086
2 to 29 Day Intervention:
Base line................... 1,416 1 1,416 0.5 708
Exit........................ 872 1 872 0.5 436
Subtotal.................... 1,416 .............. 2,288 .............. 1,144
Single Day Intervention:
Exit........................ 2,458 1 2,458 0.25 614
Annualized Total............ 11,811 .............. 20,512 .............. 14,844
----------------------------------------------------------------------------------------------------------------
Table 1b--Estimates of Annualized Hour Burden by Survey Type
--------------------------------------------------------------------------------------------------------------------------------------------------------
Questionnaire Number of respondents Total responses Total hour burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annualized Total Adult........................................ 9,682 16,899 12,234
Annualized Total Youth........................................ 2,128 3,612 2,610
-----------------------------------------------------------------------------------------
Annualized Total...................................... 11,811 20,512 14,844
--------------------------------------------------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent by November 2, 2011 to the SAMHSA
Desk Officer at the Office of Information and Regulatory Affairs,
Office of Management and Budget (OMB). To ensure timely receipt of
comments, and to avoid potential delays in OMB's receipt and processing
of mail sent through the U.S. Postal Service, commenters are encouraged
to submit their comments to OMB via e-mail to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send
their comments via e-mail, commenters may also fax their comments to:
202-395-7285.
[[Page 61110]]
Commenters may also mail them to: Office of Management and Budget,
Office of Information and Regulatory Affairs, New Executive Office
Building, Room 10102, Washington, DC 20503.
Rose Shannon,
Director, Division of Executive Correspondence.
[FR Doc. 2011-25374 Filed 9-30-11; 8:45 am]
BILLING CODE 4162-20-P
